Fortress Biotech Q3 net revenue rises, driven by dermatology sales

By Reuters News


Overview

  • US biopharma firm's Q3 net revenue rose 9% yr/yr to $19.2 mln

  • Company posted Q3 net loss of $8.25 mln, reversing a profit last year

  • Fortress repaid $15 mln credit facility, leaving no parent-level debt


Outlook

  • Company did not provide specific financial guidance for future periods in its press release


Result Drivers

  • DERMATOLOGY SALES - Co said higher net revenue was mainly driven by increased sales of marketed dermatology products through Journey Medical

  • EMROSI PRESCRIPTIONS - Journey Medical reported approximately 40,000 Emrosi prescriptions in Q3, supported by improved reimbursement mix

  • ROYALTY INCOME - Co cited growing royalty income from ZYCUBO and UNLOXCYT as contributing to results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$8.25 mln

Q3 Income from Operations

-$7.19 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • Wall Street's median 12-month price target for Fortress Biotech Inc is $5.00, about 151.3% above its November 12 closing price of $1.99


Reuters Recommended Reads

  • Nov 12 - Journey Medical's Q3 revenue rises on Emrosi demand but misses estimates

  • Nov 12 - EyePoint Pharmaceuticals Q3 revenue falls, net loss widens

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk